April 9, 2014
This article was reported by Medical Xpress.
Medical Xpress reported on ongoing research in nano-technology aimed at making HIV drug treatment more effective. Researchers at the University of Liverpool in the United Kingdom have been working on nano-sized particles of antiretrovirals to improve their stability and absorption. They have found that some treatments are not compatible with the technology and are now working in collaboration with the Clinton Health Access Initiative (CHAI) to improve the capabilities of the nano-technology. Professor Andrew Owen, University of Liverpool pharmacologist, and Dr. Paul L. Domanico, CHAI senior director of research and development, are leading the project. The researchers will experiment with a commonly used HIV drug and combine it with other generally used ingredients to create stable nano-particles.
Nano-medicine can benefit patients by increasing the amount of drug where it is needed. The goal of this research is to prevent the drug from degenerating during passage through the intestines by using nano-particles. In this way, the body will absorb more of the drug into the body to fight the virus. With more of the drug being absorbed where it is needed, patients can take a lower dosage to achieve the therapeutic effect.
The research builds on HIV work completed between the university's Department of Molecular and Clinical Pharmacology and Department of Chemistry, and will support CHAI's existing and current preclinical pharmacology studies. State-of- the-art mathematical modelling techniques will bridge between both. The researchers expect to begin clinical trials later this year.
No comments have been made.